Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01901146
Title Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Subjects With HER2 Positive Early Breast Cancer (Lilac)
Recruitment Completed
Gender female
Phase Phase III
Variant Requirements No
Sponsors Amgen
Indications

Her2-receptor positive breast cancer

Therapies

Cyclophosphamide + Epirubicin

Paclitaxel + Trastuzumab

Age Groups: adult
Covered Countries CAN


No variant requirements are available.